Drug Trial Radar · NCT01972529
Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure
Last checked: Nov 20, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Feb 2014
Primary completion
Jan 26, 2017
Study completion Feb 27, 2017
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Oct 30, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag to treat adults with thrombocytopenia associated with liver disease. The study will evaluate avatrombopag in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce the need for platelet transfusions or any rescue procedure for bleeding due to procedural and post-procedural bleeding complications. Participants will be enrolled into 2 cohorts according to mean baseline platelet count and, within each baseline platelet count cohort will be further stratified by risk of bleeding associated with the elective procedure (low, moderate, or high) and hepatocellular carcinoma (HCC) status (Yes or No).
Conditions
- Thrombocytopenia Associated With Liver Disease
Interventions
avatrombopag (lower baseline platelet count)Drug
60 mg avatrombopag (3 x 20 mg tablets)
placebo (lower baseline platelet count)Drug
60 mg placebo (3 x 20 mg matching placebo tablets)
avatrombopag (higher baseline platelet count)Drug
40 mg avatrombopag (2 x 20 mg tablets)
placebo (higher baseline platelet count)Drug
40 mg placebo (2 x 20 mg matching placebo tablets)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled ProcedureTime frame: Baseline (Visit 2) up to 7 days following a scheduled procedure
Locations
109 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Lancaster, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
San Bernardino, California
Site not named
San Francisco, California
Site not named
Jacksonville, Florida
Site not named
Palmetto Bay, Florida
Site not named
Tampa, Florida
Site not named
New Orleans, Louisiana
Site not named
Rochester, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Jackson, Mississippi
Site not named
New York, New York
Site not named
The Bronx, New York
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Dallas, Texas
Site not named
Harlingen, Texas
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Ciudad Autonoma Buenos Aires, Argentina
Site not named
Mendoza, Argentina
Site not named
Pilar, Buenos Aires, Argentina
Site not named
Camperdown, New South Wales, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Bedford Park, South Australia, Australia
Site not named
Linz, Austria
Site not named
Vienna, Austria
Site not named
Brussels, Belgium
Site not named
Leuven, Belgium
Site not named
São Paulo, Brazil
Site not named
Porto Alegre, Rio Grande do Sul, Brazil
Site not named
São José do Rio Preto, São Paulo, Brazil
Site not named
London, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
La Serena, Chile
Site not named
Santiago, Chile
Site not named
Beijing, China
Site not named
Changsha, Hu'nan, China
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.